1.5 mg/0.5 mL The first and ONLY GLP1-RA to Demonstrate Primary and Secondary CVD Prevention†,1,2,3 †Trulicity® demonstrates primary and secondary prevention of major adverse cardiovascular events (MACE)* in patients with type 2 diabetes at cardiovascular risk.1 *3-component MACE in REWIND (nonfatal stroke, nonfatal myocardial infarction, or death). Trulicity® significantly reduced the risk of MACE-3 by 12% despite a majority of patients not having established cardiovascular disease¹ ADA/EASD Guideline Strongest evidence for Dulaglutide for primary prevention, but lacking for other GLP1-RAs2* Powerful HbA1c Reduction Trulicity® proves powerful HbA1c reductions of up to -1.6% across a range of head-to-head clinical trials3 No titration required³ Simple injection Once weekly3 Hidden needle4 No mixing or reconstitution required4 PP-DG-ZA-0332 Exp: 09/2023 Reference: 1.Gerstein HC et al. Lancet. 2019 Jun 7. pii: S0140-6736(19)31149-3. doi: 10.1016/S0140-6736(19)31149-3. [Epub ahead of print]. 2.TBuse, J.B., Wexler, D.J., Tsapas, A. et al. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 63, 221–228 (2020). https://doi.org/10.1007/s00125-019-05039-w 3.Trulicity® (dulaglutide once weekly) Trulicity® Professional Information , Eli Lilly and Company, Johannesburg, South Africa - 2020. 4.Trulicity® Instructions for use , Eli Lilly and Company, Johannesburg, South Africa - 2020 ADA=American Diabetes Association; CV=cardiovascular; CVD=cardiovascular diseases; EASD=European Association for the Study of Diabetes; GLP-1 RA=glucagon-like peptide-1 receptor agonists; MACE=major adverse cardiovascular events; MI=myocardial infarction. Trulicity®. Reg No. 51/21.13/0344 Dulaglutide 1,5 mg/ 0,5ml solution for injection. For more product information, please email us at: za_medinfo@lilly.com For full prescribing information, refer to the Professional Information approved by the medicines regulatory authority Eli Lilly (S.A.) (Pty) Ltd. Reg. No. 1957/000371/07 1st Floor, Golden Oak House, Ballyoaks Office Park, 35 Ballyclare Drive, Bryanston, Johannesburg Tel: +27 (11) 510 9300 © 2020 Eli Lilly and Company. All Rights Reserved. S4
RkJQdWJsaXNoZXIy NDIzNzc=